[1]王 璐,刘 敏.乳腺癌患者血清中B7-同源物2和B7-同源物3的表达及临床意义[J].新乡医学院学报,2022,39(9):827-832.[doi:10.7683/xxyxyxb.2022.09.006]
 WANG Lu,LIU Min.Expression and clinical significance of B7 homolog 2 and B7 homolog 3 in serum of patients with breast cancer[J].Journal of Xinxiang Medical University,2022,39(9):827-832.[doi:10.7683/xxyxyxb.2022.09.006]
点击复制

乳腺癌患者血清中B7-同源物2和B7-同源物3的表达及临床意义
分享到:

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
39
期数:
2022年9
页码:
827-832
栏目:
临床研究
出版日期:
2022-09-05

文章信息/Info

Title:
Expression and clinical significance of B7 homolog 2 and B7 homolog 3 in serum of patients with breast cancer
作者:
王 璐1刘 敏2
(1.南京中医药大学,江苏 南京 210023;2.南京中医药大学附属苏州市中医医院肿瘤科,江苏 苏州 215000)
Author(s):
WANG Lu1LIU Min2
(1.Nanjing University of Chinese Medicine,Nanjing 210023,Jiangsu Province,China;2.Department of Oncology,Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine,Suzhou 215000,Jiangsu Province,China)
关键词:
乳腺癌B7-同源物2B7-同源物3诊断
Keywords:
breast cancerB7 homolog 2B7 homolog 3diagnosis
分类号:
R737.9
DOI:
10.7683/xxyxyxb.2022.09.006
文献标志码:
A
摘要:
目的 探讨乳腺癌患者血清中B7-同源物2(B7-H2)和B7-同源物3(B7-H3)的表达及临床意义。方法 选择2018年1月至2019年6月南京中医药大学附属苏州市中医医院收治的乳腺癌患者45例为乳腺癌组,另选择同期于本院体检中心体检健康者25例为对照组。采用酶联免疫吸附法检测2组受试者血清中B7-H2、B7-H3 表达水平;通过查阅病历采集乳腺癌患者的年龄、肿瘤直径、TNM分期、病理类型、远处转移、淋巴结转移及雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体-2(HER-2)表达等临床病理特征,分析乳腺癌患者血清中B7-H2、B7-H3 表达水平与患者临床病理特征的关系;采用受试者操作特征(ROC)曲线分析B7-H2、B7-H3单独及联合检测对乳腺癌的诊断价值。结果 乳腺癌组患者血清中B7-H2、B7-H3表达水平显著高于对照组(P<0.05)。乳腺癌患者血清B7-H2表达水平与患者的年龄、肿瘤直径、TNM分期、病理类型、远处转移、淋巴结转移及ER、PR、HER-2表达均无关(P>0.05);B7-H3表达水平与患者的TNM分期、淋巴结转移、远处转移有关(P<0.05),与年龄、肿瘤直径、病理类型及ER、PR、HER-2表达无关(P>0.05)。乳腺癌患者血清中B7-H2与B7-H3表达呈正相关(r=0.307,P<0.05)。血清中B7-H2、B7-H3单独检测诊断乳腺癌的灵敏度分别为75.6%、91.1%,特异度分别为96.0%、84.0%;B7-H2 与B7-H3联合检测诊断乳腺癌的灵敏度为93.3%,特异度为88.0%。血清中B7-H2、B7-H3单独和联合检测诊断乳腺癌的ROC曲线下面积(AUC)分别为0.866、0.895、0.959;B7-H2联合B7-H3诊断乳腺癌的AUC显著高于B7-H2(Z=2.348,P<0.05),B7-H2联合B7-H3与B7-H3单独检测诊断乳腺癌的AUC比较差异无统计学意义(Z=1.938,P>0.05),B7-H2与B7-H3单独检测诊断乳腺癌的AUC比较差异无统计学意义(Z=0.466,P>0.05)。结论 B7-H2、B7-H3可能参与乳腺癌的发生、发展,血清中B7-H3表达水平可反映乳腺癌患者的恶性程度,可作为判断乳腺癌预后的一个指标;B7-H2、B7-H3对诊断乳腺癌具有较高的灵敏度和特异度,B7-H2联合B7-H3能提高对乳腺癌的诊断效能。
Abstract:
Objective To investigate the expression and clinical significance of B7 homolog 2(B7-H2) and B7 homolog 3(B7-H3) in serum of patients with breast cancer.Methods A total of 45 patients with breast cancer admitted to Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine from January 2018 to June 2019 were selected as the breast cancer group,and 25 healthy people who underwent physical examination in the physical examination center of our hospital during the same period were selected as the control group.The levels of B7-H2 and B7-H3 in serum of subjects in the two groups were detected by enzyme-linked immunosorbent assay.The clinicopathological feature including age,tumor diameter,TNM stage,pathological types,distant metastasis,lymphatic metastasis and the expression of estrogen receptor(ER),progesterone receptor(PR),human epidermal growth factor receptor-2 (HER-2) of breast cancer patients were collected by consulting medical records,and the relationship between the serum B7-H2,B7-H3 levels and clinicopathological characteristics of breast cancer patients was analyzed;the diagnostic value of single and combined detection of B7-H2 and B7-H3 for breast cancer was analyzed by using receiver operator characteristic(ROC).Results The levels of B7-H2 and B7-H3 in serum of patients with breast cancer were significantly higher than those in the control group(P<0.05).The level of B7-H2 was not correlated with age,tumor diameter,TNM stage,pathological pattern,distant metastasis,lymphatic metastasis and the expression of ER,PR and HER-2 in breast cancer patients (P>0.05).The level of B7-H3 was correlated with TNM stage,lymphatic metastasis and distant metastasis (P<0.05),and it was not correlated with age,tumor diameter,pathological pattern and the expression of ER,PR and HER-2(P>0.05).There was a positive correlation between the level of B7-H2 and B7-H3 in serum of breast cancer patients (r=0.307,P<0.05).The sensitivity of serum B7-H2 and B7-H3 levels in the diagnosis of breast cancer was 75.6% and 91.1%,respectively;and the specificity of serum B7-H2 and B7-H3 levels in the diagnosis of breast cancer was 96.0% and 84.0%,respectively.The sensitivity and specificity of combined detection of B7-H2 and B7-H3 were 93.3%,88.0%,respectively.The area under the curve(AUC) of ROC of single and combined detection of B7-H2 and B7-H3 in the diagnosis of breast cancer was 0.866,0.895 and 0.959,respectively;the AUC of B7-H2 combined with B7-H3 in the diagnosis of breast cancer was significantly higher than that of B7-H2 (Z=2.348,P<0.05).There was no significant difference in the AUC of B7-H2 combined with B7-H3 compared with that of B7-H3 alone in the diagnosis of breast cancer (Z=1.938,P>0.05),and there was no significant difference in the AUC of B7-H2 compared with that B7-H3 alone in the diagnosis of breast cancer (Z=0.466,P>0.05).Conclusion B7-H2 and B7-H3 may be involved in the occurrence and development of breast cancer.The level of B7-H3 in serum can reflect the degree of malignancy of breast cancer patients,and it can be used as an indicator to judge the prognosis of breast cancer;B7-H2 and B7-H3 have high sensitivity and specificity for the diagnosis of breast cancer,B7-H2 combined with B7-H3 can improve the diagnostic efficiency of breast cancer.

参考文献/References:

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality Worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[2] 国家肿瘤质控中心乳腺癌专家委员会,中国抗癌协会乳腺癌专业委员会,中国抗癌协会肿瘤药物临床研究专业委员会.中国晚期乳腺癌规范诊疗指南(2020)[J].中华肿瘤杂志,2020,42(10):781-797.
BREAST CANCER EXPERT COMMITTEE OF NATIONAL CANCER QUALITY CONTROL CENTER,BREAST CANCER EXPERT COMMITTEE OF CHINA ANTI-CANCER ASSOCIATION,CANCER DRUG CLINICAL RESEARCH COMMITTEE OF CHINA ANTI-CANCER ASSOCIATION.Guidelines for clinical diagnosis and treatment of advanced breast cancer in China (2020 edition)[J].Chin J Oncol,2020,42(10):781-797.
[3] 金玉芬,张婷,姜新,等.B7-H3在结直肠癌中的研究进展[J].癌症进展,2020,18(17):1740-1743,1829.
JIN Y F,ZHANG T,JIANG X,et al.Research progress of B7-H3 in colorectal cancer[J].Cancer Progress,2020,18(17):1740-1743,1829.
[4] 刘德总,杨颖涛.乳腺癌辅助治疗现状与展望[J].新乡医学院学报,2021,38(8):781-789,793.
LIU D Z,YANG Y T.Current situation and prospect of adjuvant therapy for breast cancer[J].J Xinxiang Med Univ,2021,38(8):781-789,793.
[5] 杨永昌,常帅,刘杰.免疫检查点分子B7-H3在肿瘤中作用的研究进展[J].标记免疫分析与临床,2021,28(4):692-696.
YANG Y C,CHANG S,LIU J.The research progress of immune checkpoint B7-H3 in tumor[J].Labeled Immunoassay Clin Med,2021,28(4):692-696.
[6] 王萱,南丁阿比雅思,杨悦,等.B7-H3的作用机制及其在非小细胞肺癌中的研究新进展[J].现代肿瘤医学,2019,27(24):4485-4488.
WANG X,NADINGABIYASI,YANG Y,et al.New progress on the mechanism of B7-H3 and its clinical significance in non-small cell lung cancer[J].J Mod Oncol,2019,27(24):4485- 4488.
[7] 董贺婷,陈正荣,季伟.可诱导共刺激分子配体的研究进展[J].江苏医药,2020,46(2):195-198.
DONG H T,CHEN Z R,JI W.Research progress of inducible costimulatory molecular ligands[J].Jiangsu Med J,2020,46(2):195-198.
[8] ZHENG Y,LIAO N,WU Y,et al.High expression of B7-H2 or B7-H3 is associated with poor prognosis in hepatocellular carcinoma[J].Mol Med Rep,2019,19(5):4315-4325.
[9] DESANTIS C E,MA J,GAUDET M M,et al.Breast cancer statistics,2019[J].CA Cancer J Clin,2019,69(6):438-451.
[10] 张佳,李宏江.乳腺癌免疫检查点抑制剂研究进展[J].西部医学,2021,33(11):1708-1713.
ZHANG J,LI H J.Progress in immunocheckpoint inhibitors for breast cancer[J].Med J West Chin,2021,33(11):1708-1713.
[11] MITTENDORFE A,PHILIPS A V,MERICBER N,et al.PD-L1 expression in triple-negative breast cancer[J].Cancer Immunol Res,2014,2( 4):361-370.
[12] 王晓稼.乳腺癌的免疫治疗策略[J].中国肿瘤外科杂志,2020,12(4):301-305.
WANG X J.Immunotherapy strategies for breast cancer[J].Chin J Surg Oncol,2020,12(4):301-305.
[13] EMENS L A,ADAMS S,BARRIOS C H,et al.First-line atezolizumab plus nab-paclitaxel for unresectable,locally advanced,or metastatic triple-negative breast cancer:IMpassion130 final overall survival analysis[J].Ann Oncol,2021,32(8):983-993.
[14] CORTES J,CESCON D W,RUGO H S,et al.Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355):a randomised,placebo-controlled,double- blind,phase 3 clinical trial[J].Lancet,2020,396(10265):1817-1828.
[15] DI SPAZIO L,RIVANO M,CANCANELLI L,et al.The degree of programmed death-ligand 1(PD-L1) positivity as a determinant of outcomes in metastatic triple-negative breast cancer treated with first-line immune checkpoint inhibitors[J].Cureus,2022,14(1):e21065.
[16] TOLANEY S M,BARROSO-SOUSA S R,KEENAN T,et al.Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor-positive,ERBB2-negative metastatic breast cancer:a randomized clinical trial[J].JAMA Oncol,2020,6(10):1598-1605.
[17] WANG F,YAN T,CHEN L,et al.Involvement of inducible costimulator ligand (ICOSL) expression in thyroid tissue in hyperthyroidism of Graves′ disease patients[J].J Clin Immunol,2012,32(6):1253-1261.
[18] 曹婷华.结直肠癌微环境中B7-H2在CD8+T细胞的表达及临床意义[D].苏州:苏州大学,2017.
CAO T H.Expression of B7-H2 in CD8+T cells in colorectal cancer microenvironment and its clinical significance[D].Suzhou:Soochow Univ,2017.
[19] 马晓天,郭振红.共信号分子功能及其在肿瘤治疗中的应用[J].中国肿瘤生物治疗杂志,2021,28(12):1219-1226.
MA X T,GUO Z H.The functions of co-signaling molecules and their clinical applications in cancer therapy[J].Chin J Cancer Biother,2021,28(12):1219-1226.
[20] SOLINAS C,GU-TRANTIEN C,WILLARD-GALLO K.The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy[J].ESMO Open,2020,5(1):e000544.
[21] KUMAWAT A K,STRID H,TYSK C,et al.Microscopic colitis patients demonstrate a mixed Th17/Tc17 and Th1/Tc1 mucosal cytokine profile[J].Mol Immunol,2013,55(3-4):355-364.
[22] CURIEL T J,COUKOS G,ZOU L,et al.Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival[J].Nat Med,2004,10(9):942-949.
[23] KANG F B,WANG L,JIA H C,et al.B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway[J].Cancer Cell Int,2015,15:45.
[24] 何桦波,武伟,徐静芳.外周血B7-H2联合白细胞介素-6水平变化在胆管癌诊断及预后评估中的价值[J].中国卫生检验杂志,2019,29(11):1334-1336,1339.
HE H B,WU W,XU J F.The value of peripheral blood B7-H2 combined with interleukin 6 level in the diagnosis and prognosis of cholangiocarcinoma[J].Chin J Health Lab Technol,2019,29(11):1334-1336,1339.
[25] WANG B,JIANG H Y,ZHOU T Y,et al.Expression of ICOSL is associated with decreased survival in invasive breast cancer[J].Peer J,2019,7:e6903.
[26] ZHANG G,XU Y,ZHANG S,et al.The ICOSL expression predicts better prognosis for nasopharyngeal carcinoma via enhancing oncoimmunity[J].Biomed Res Int,2020,2020:9756732.
[27] WANG L,KANG F B,SHAN B E.B7-H3-mediated tumor immunology:friend or foe[J].Int J Cancer,2014,134(12):2764-2771.
[28] CHAPOVAL A I,NI J,LAU J S,et al.B7-H3:a costimulatory molecule for T cell activation and IFN-gamma production[J].Nat Immunol,2001,2(3):269-274.
[29] KIM J Y,LEE E,PARK K,et al.Immune signature of metastatic breast cancer:identifying predictive markers of immunotherapy response[J].Oncotarget,2017,8(29):47400-47411.
[30] 于超.乳腺癌患者血清中sB7-H3相关临床价值的初步研究[D].青岛:青岛大学,2020.
YU C.Preliminary study on the clinical value of sB7-H3 in serum of breast cancer patients[D].Qingdao:Qingdao University,2020.
[31] 杜贞华.可溶性B7-H3在乳腺癌血清中的表达及意义[D].济南:山东大学,2011.
DU Z H.The expression of serum soluble B7-H3 in breast cancer and the clinical significance[D].Jinan:Shandong University,2011.

相似文献/References:

[1]张光谋,吴俊琢,徐振平,等.抗细胞凋亡基因bcl一2在乳腺癌中的表达[J].新乡医学院学报,2001,18(03):160.
[2]刘玉生 . 万里,李森恺.乳腺癌切除即期乳房再造[J].新乡医学院学报,2001,18(01):023.
[3]王承正,张锦瑜,邱树升,等.C—erbB一2与ER、PS一2在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[4]王承正,张锦瑜,邱树升,等.C2erbB22 与ER、PS22 在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[5]王志民,段西华,祁天义,等.多点皮瓣固定法预防乳腺癌术后皮下积液效果观察 [J].新乡医学院学报,2007,24(03):287.
[6]郭兰青.乳腺癌患者生活质量影响因素[J].新乡医学院学报,2008,25(06):637.
[7]曹兴玥,赵庆伟,靳艳,等.CD44和nm23在乳腺浸润性导管癌中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):042.
[8]靳艳,曹兴玥,赵庆伟,等.CD62P在人乳腺癌组织中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):045.
[9]王 乐,王静萱,张清媛.乳腺癌骨转移靶向治疗进展[J].新乡医学院学报,2015,32(09):887.
[10]杨绍英,刘朝荣,张志刚,等.乳腺癌新辅助化学治疗前后雌激素受体、乳激素受体、Ki-67抗原和人类表皮生长因子受体-2的表达[J].新乡医学院学报,2017,34(2):125.[doi:10.7683/xxyxyxb.2017.02.012]
 YANG Shao-ying,LIU Chao-rong,ZHANG Zhi-gang,et al.Expressions of estrogen receptor,progestin recetor,Ki-67 antigen,and human epidermal growth factor receptor 2 before and after neoadjuvant chemotherapy in patients with breast cancer[J].Journal of Xinxiang Medical University,2017,34(9):125.[doi:10.7683/xxyxyxb.2017.02.012]

更新日期/Last Update: 2022-09-05